Brazil-based multinational company (MNC) Eurofarma has announced an investment in US immunotherapy developer Abcuro as part of a broader program to invest up to USD 100 million in potentially disruptive startups and biotechnology companies in the discovery and development phase. This 5-year project aims to support up to 25 companies with a limit of USD 5 million each, focusing on precision medicine, genetic editing, new targets, and artificial intelligence (AI)-assisted drug discovery for interventions such as small molecules, monoclonal antibodies (mAbs), conjugates, and gene therapies.
Eurofarma’s Commitment to Research and Development
According to Eurofarma, the company has already invested over BRL 600 million (USD 120 million) in research and development (R&D) and licensing in its homeland this year. This significant investment underscores Eurofarma’s commitment to driving innovation in the pharmaceutical industry and expanding its global footprint through strategic partnerships and investments.
The Impact of Eurofarma’s Investment on the Biotech Sector
Eurofarma’s investment in Abcuro and its broader initiative to support innovative biotechnology companies is expected to have a substantial impact on the industry. By providing financial backing and resources to companies at the forefront of precision medicine and genetic editing, Eurofarma is positioning itself as a key player in the development of new treatments and therapies that could transform patient care.-Fineline Info & Tech
